Poly(ADP-ribosyl)ation is one of the most pertinent post translational modifications involved in regulation of
chromatin structure, cell cycle progression, tissue development and differentiation and other vital biological phenomena.
The enzymes that catalyze the synthesis and degradation of poly(ADP) ribose polymers are PARP and PARG, respectively.
The role of PARP has been implicated in development of various diseases since a long time and hence it has
evolved as an important pharmacological target but a plethora of drawbacks associated with PARP inhibitors compelled
the shift of focus towards PARG. Recently PARG has evolved as an alternative target to overcome the hurdles being
faced in the treatment of various conditions like multiple organ failure, ischemic organ damage, diabetic nephropathy,
neurodegenerative diseases and cancer. The review provides a compendium on PARG, its mode of action, inhibitors, and
its therapeutic applications and also discusses the reasons due to which PARG inhibitors have not been able to reach the
clinical trials. PARG inhibitors, though far from success, definitely appear as alluring topics for further research as PARG
emerges out as an eminent pharmacological target in making which can shape the future of medicines to provide better
therapy with reduced side effects and more efficiency.
Keywords: Cancer, inflammatory diseases, ischemic diseases, PARG, PARG inhibitors, PARP.
Rights & PermissionsPrintExport